4.3 Editorial Material

Severe multiple sclerosis reactivation after gonadotropin treatment

期刊

MULTIPLE SCLEROSIS AND RELATED DISORDERS
卷 22, 期 -, 页码 38-40

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2018.02.031

关键词

Multiple sclerosis; Autoimmune diseases

资金

  1. Biogen Idec
  2. Merck
  3. Genzyme
  4. Novartis
  5. Biogen
  6. Teva
  7. Biogen Novartis

向作者/读者索取更多资源

Several reports indicate increased disease activity in patients with multiple sclerosis (MS) undergoing assisted reproductive techniques (ART), in the form of gonadtopin releasing hormone (GnRH) agonists. Other forms of ART treatments, like gonadotropin-treatment, have therefore been considered a safer option for MS-patients. We present a patient who despite being completely clinically and radiologically stable for eight years during disease modifying therapy experienced a nearly fulminant disease course almost immediately after starting gonadotropin- treatment, indicating that this form of follicle stimulating treatment could also be a major risk factor for MS disease activity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据